Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Core Viewpoint - Coherus Oncology, Inc. has successfully closed a public offering of 28,600,000 shares at a price of $1.75 per share, raising approximately $50.1 million to support its clinical development and commercialization efforts [1][3][4]. Group 1: Offering Details - The public offering was led by healthcare-focused investors including Janus Henderson Investors, HBM Healthcare Investments, and Samsara BioCapital [2]. - The gross proceeds from the offering were approximately $50.1 million, with a 30-day option for underwriters to purchase an additional 4,290,000 shares [1][4]. - The offering was conducted under an effective shelf registration statement previously filed with the SEC [5]. Group 2: Company Strategy and Use of Proceeds - Coherus aims to utilize the net proceeds from the offering to support the commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of its product candidates, and for general corporate purposes [4]. - The company has significantly improved its financial position by reducing debt by over 80% and transitioning from a biosimilar company to a clinical-stage biotech focused on innovative oncology [3]. Group 3: Product Pipeline - Coherus has an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes mid-stage clinical candidates targeting various cancers [7]. - The innovative oncology pipeline includes multiple antibody immunotherapy candidates designed to enhance immune responses against tumors [8].